Prolexys Licenses the Prolexys Human Interactome Database to GlaxoSmithKline
News Oct 04, 2005
Prolexys Pharmaceuticals, Inc. has announced that it has completed a non-exclusive license agreement with GlaxoSmithKline for the Prolexys Human Interactome Database.
This database contains over 258,000 human protein-protein interactions, representing approximately one half of all RefSeq entries.
The dataset was built from a wide range of human cell and tissue types using the Company's HyNet™ system, a highly automated high-throughput yeast 2-hybrid process.
This system is designed to give a strong preference to high confidence interactions and the quality of the data has been demonstrated in a variety of tests.
“This asset adds significant value to state-of-the-art pharmaceutical research programs in the areas of novel target identification, target validation, improved understanding of disease biology, and efficient choice of research direction,” said Dr. Sudhir Sahasrabudhe, Chief Scientific Officer of Prolexys.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.